$RGEN
REPLIGEN CORP

2014 Q4 Form 10-K Financial Statement

#000119312516478518 Filed on February 25, 2016

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $16.39M $15.28M $15.55M
YoY Change 6.57% -18.83% -11.18%
Cost Of Revenue $8.084M $6.931M $6.671M
YoY Change 74.71% 22.48% 25.92%
Gross Profit $8.309M $8.347M $8.880M
YoY Change -22.74% -36.59% -27.28%
Gross Profit Margin 50.69% 54.63% 57.1%
Selling, General & Admin $4.975M $4.471M $4.326M
YoY Change 47.76% 54.07% 38.48%
% of Gross Profit 59.87% 53.56% 48.72%
Research & Development $1.328M $1.650M $1.430M
YoY Change -6.61% 15.38% -37.99%
% of Gross Profit 15.98% 19.77% 16.1%
Depreciation & Amortization $1.060M $1.100M $970.0K
YoY Change 26.19% 44.74% 40.58%
% of Gross Profit 12.76% 13.18% 10.92%
Operating Expenses $6.303M $6.121M $5.756M
YoY Change 31.61% 41.3% 6.0%
Operating Profit $61.00K $2.216M $3.106M
YoY Change -98.82% -72.44% -49.11%
Interest Expense $12.00K $11.00K $13.00K
YoY Change -88.0% -6.02% 4.82%
% of Operating Profit 19.67% 0.5% 0.42%
Other Income/Expense, Net $134.0K -$14.00K $65.00K
YoY Change -348.15% -137.84% -153.28%
Pretax Income $242.0K $2.255M $3.243M
YoY Change -95.36% -72.31% -46.25%
Income Tax $640.0K $789.0K $418.0K
% Of Pretax Income 264.46% 34.99% 12.89%
Net Earnings -$398.0K $1.466M $2.825M
YoY Change -111.96% -75.1% -37.76%
Net Earnings / Revenue -2.43% 9.6% 18.17%
Basic Earnings Per Share -$0.01 $0.04 $0.09
Diluted Earnings Per Share -$0.01 $0.04 $0.09
COMMON SHARES
Basic Shares Outstanding 32.75M shares 32.68M shares 32.23M shares
Diluted Shares Outstanding 32.75M shares 33.33M shares 33.08M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.50M $54.10M $50.00M
YoY Change -5.03% -14.13% -13.94%
Cash & Equivalents $35.36M $35.91M $33.76M
Short-Term Investments $23.10M $18.20M $16.30M
Other Short-Term Assets $23.00K $1.200M $1.600M
YoY Change -31.03% -20.0% -20.0%
Inventory $12.38M $13.34M $12.82M
Prepaid Expenses
Receivables $7.760M $7.053M $9.004M
Other Receivables $200.0K $0.00 $400.0K
Total Short-Term Assets $80.95M $75.69M $73.86M
YoY Change -6.26% -13.44% -8.72%
LONG-TERM ASSETS
Property, Plant & Equipment $14.53M $13.19M $12.55M
YoY Change 16.12% 7.32% 27.57%
Goodwill $14.19M $14.14M $13.35M
YoY Change 1327.06% 1322.94% 1243.26%
Intangibles $14.64M $15.35M $16.12M
YoY Change 136.54% 136.8% 148.03%
Long-Term Investments $3.600M $10.00M $11.90M
YoY Change -70.49% 143.9% 158.7%
Other Assets $500.0K $500.0K $500.0K
YoY Change 25.0% 66.67% -72.22%
Total Long-Term Assets $47.35M $53.14M $55.19M
YoY Change 46.61% 119.63% 132.48%
TOTAL ASSETS
Total Short-Term Assets $80.95M $75.69M $73.86M
Total Long-Term Assets $47.35M $53.14M $55.19M
Total Assets $128.3M $128.8M $129.0M
YoY Change 8.13% 15.4% 23.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.863M $2.763M $3.896M
YoY Change 124.4% 197.2% 163.02%
Accrued Expenses $6.819M $7.708M $4.920M
YoY Change -28.82% -1.87% -43.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.68M $10.47M $8.815M
YoY Change -5.48% 19.2% -13.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.879M $3.688M $4.663M
YoY Change 70.03% 36.8% 135.07%
Total Long-Term Liabilities $5.879M $3.688M $4.663M
YoY Change 70.03% 36.8% 135.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.68M $10.47M $8.815M
Total Long-Term Liabilities $5.879M $3.688M $4.663M
Total Liabilities $16.56M $14.16M $13.48M
YoY Change 12.21% 23.33% 10.46%
SHAREHOLDERS EQUITY
Retained Earnings -$80.89M -$80.49M -$81.95M
YoY Change -9.17% -12.88% -16.6%
Common Stock $198.4M $327.0K $326.6K
YoY Change 3.9% 2.57% 2.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.7M $114.6M $115.6M
YoY Change
Total Liabilities & Shareholders Equity $128.3M $128.8M $129.0M
YoY Change 8.13% 15.4% 23.31%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income -$398.0K $1.466M $2.825M
YoY Change -111.96% -75.1% -37.76%
Depreciation, Depletion And Amortization $1.060M $1.100M $970.0K
YoY Change 26.19% 44.74% 40.58%
Cash From Operating Activities $1.750M $6.330M $2.320M
YoY Change -74.86% -3.8% -73.64%
INVESTING ACTIVITIES
Capital Expenditures -$2.640M -$1.740M -$620.0K
YoY Change 206.98% -34.59% -21.52%
Acquisitions
YoY Change
Other Investing Activities $1.420M $20.00K -$17.19M
YoY Change -115.5% -96.67% -86050.0%
Cash From Investing Activities -$1.220M -$1.720M -$17.81M
YoY Change -87.84% -16.91% 2243.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 800.0K -460.0K 840.0K
YoY Change 21.21% 170.59% -21.5%
NET CHANGE
Cash From Operating Activities 1.750M 6.330M 2.320M
Cash From Investing Activities -1.220M -1.720M -17.81M
Cash From Financing Activities 800.0K -460.0K 840.0K
Net Change In Cash 1.330M 4.150M -14.65M
YoY Change -155.19% -4.38% -260.81%
FREE CASH FLOW
Cash From Operating Activities $1.750M $6.330M $2.320M
Capital Expenditures -$2.640M -$1.740M -$620.0K
Free Cash Flow $4.390M $8.070M $2.940M
YoY Change -43.86% -12.66% -69.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33031533 shares
CY2014Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1370000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
431000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
1003000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
1647000
CY2014Q2 us-gaap Goodwill
Goodwill
13352000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
26540000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
85000
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
184000
CY2015Q2 dei Entity Public Float
EntityPublicFloat
1348697533
CY2011Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84124000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29210000
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4005174 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1610988 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2013Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
2028000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1998000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
103886000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39830000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1225117 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32774374 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.31
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32774374 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
571000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10682000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3759000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13816000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6819000
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
78000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
251000
CY2014Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
1956000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1135000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3444000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
328000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
118000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
198064000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
41000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2118000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5879000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
130000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5773000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17298000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
511000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
713000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80887000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
111732000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128293000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3844000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3863000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
26640000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
450000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14636000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1782000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4754000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14526000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3550000
CY2014Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2270000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
80946000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
628000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
23000
CY2014Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
486000
CY2014Q4 us-gaap Goodwill
Goodwill
14185000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
3069000
CY2014Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
47348000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
767000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5374000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
5000
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
9108000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35363000
CY2014Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
419000
CY2014Q4 us-gaap Interest Receivable
InterestReceivable
100000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2256000
CY2014Q4 us-gaap Assets
Assets
128293000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17431000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1674000
CY2014Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18080000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12580000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2104000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7760000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28342000
CY2014Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
5000
CY2014Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
240000
CY2014Q4 us-gaap Prepaid Taxes
PrepaidTaxes
220000
CY2014Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
3848000
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
359000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
23090000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
26643000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
133000
CY2014Q4 us-gaap Inventory Net
InventoryNet
12384000
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
13116000
CY2014Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
492000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1183574 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1240935 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2441761 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.77
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
623652 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32949353 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Share Price
SharePrice
28.29
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
559922 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.42
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.44
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32949353 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
34 Investment
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
166000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18781000
CY2015Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
30322000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4680000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16496000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1418000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12057000
CY2015Q4 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
0
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
343000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
501000
CY2015Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
1899000
CY2015Q4 us-gaap Contractual Obligation
ContractualObligation
5729000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3043000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4480000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4885000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
329000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
451000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
202527000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
31000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1289000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1888000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4708000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
258000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8566000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11497000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18514000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
269000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1289000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2204000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1434000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71542000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
122748000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1371000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146237000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6788000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6724000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2343000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
19315000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
450000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12755000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1820000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5741000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13801000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1633000
CY2015Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2808000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
103252000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1079000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22653000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1701000
CY2015Q4 us-gaap Goodwill
Goodwill
14346000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
4355000
CY2015Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
42985000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
2126000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
17688000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10671000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
12520000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1189000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
21652000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
17682000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6547000
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
13306000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54092000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12048000
CY2015Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
558000
CY2015Q4 us-gaap Interest Receivable
InterestReceivable
63000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1537000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1701000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1586000
CY2015Q4 us-gaap Assets
Assets
146237000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18564000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1150000
CY2015Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
17640000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12389000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2098000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11300000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30297000
CY2015Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
206000
CY2015Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
82000
CY2015Q4 us-gaap Prepaid Taxes
PrepaidTaxes
105000
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
425000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
455000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
19000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17682000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19326000
CY2015Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
50000
CY2015Q4 us-gaap Inventory Net
InventoryNet
17998000
CY2015Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
13758000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1522000
CY2015Q4 rgen Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost
1638000
CY2015Q4 rgen Impact Of Credit Risk On Fair Value Of Derivatives
ImpactOfCreditRiskOnFairValueOfDerivatives
0
CY2015Q4 rgen Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
1633000
CY2015Q4 rgen Prepaid Services And Professional Fees
PrepaidServicesAndProfessionalFees
689000
CY2014Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
4000000
CY2014Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
21170000
CY2014Q2 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
26540000
CY2014Q2 rgen Business Acquisition Working Capital Adjustments
BusinessAcquisitionWorkingCapitalAdjustments
-66000
CY2007Q2 rgen Stock Issued During Period Shares Common Stock Warrants
StockIssuedDuringPeriodSharesCommonStockWarrants
150000 shares
CY2007Q2 rgen Warrant Term
WarrantTerm
P7Y
CY2007Q2 rgen Common Stock Purchase Warrants Exercise Price Per Share
CommonStockPurchaseWarrantsExercisePricePerShare
0.01
CY2014Q1 rgen Lease Commencement Date
LeaseCommencementDate
2014-08-01
CY2014Q1 rgen Lease Agreement Term
LeaseAgreementTerm
P8Y1M
CY2001 rgen Lease Agreement Area
LeaseAgreementArea
25000 sqft
CY2001 rgen Lease Agreement Term
LeaseAgreementTerm
P10Y
CY2007 rgen Lease Agreement Area
LeaseAgreementArea
2500 sqft
CY2007 rgen Lease Agreement Term
LeaseAgreementTerm
P5Y
CY2011 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-05-31
CY2011 rgen Lease Agreement Area
LeaseAgreementArea
55694 sqft
CY2011 rgen Lease Agreement Term
LeaseAgreementTerm
P11Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2013 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
739626 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5139 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
187000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5363 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.022 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31667015 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.301 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.053 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
25930000
CY2013 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.56
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0109 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.31
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0208 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32406641 shares
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.50
CY2013 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.58
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2400000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16180000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4635000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2522000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1060000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-110000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
22873000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
10231000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
626000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23014000
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
CY2013 us-gaap Revenues
Revenues
68169000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
774000
CY2013 us-gaap Investment Income Net
InvestmentIncomeNet
301000
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
47482000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1736000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
12783000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58000
CY2013 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2013 us-gaap Net Income Loss
NetIncomeLoss
16093000
CY2013 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
16403000000
CY2013 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
803000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42480000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
991000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
20687000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
106000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
1264000
CY2013 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
76331000000
CY2013 us-gaap Interest Expense
InterestExpense
50000
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
74000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2437000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3114000
CY2013 us-gaap Depreciation
Depreciation
2092000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2522000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1022000
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1306000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
7825000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6921000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
29209000
CY2013 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
91000
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
3322000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1122000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4124000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3723000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
45296000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2788000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10620000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-509000
CY2013 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
2682000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1228000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-734000
CY2013 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
2293000
CY2013 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
72000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1060000
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12701000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1257000
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
9000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17906000
CY2013 us-gaap Cost Of Goods Sold
CostOfGoodsSold
22481000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2450000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7341000
CY2013 rgen Royalty Payment Rate
RoyaltyPaymentRate
0.15 pure
CY2013 rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.013 pure
CY2013 rgen Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
1201000
CY2013 rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-298000
CY2013 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
2797000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
766010 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5100 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011 pure
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
307475 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5171 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.065 pure
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32497657 shares
CY2014 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.267 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.132 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
18401000
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.27
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0188 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.12
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0211 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33263667 shares
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002 pure
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.28
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-6557000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7771000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
3117000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7743000
CY2014 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
250000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
2547000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
399000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5602000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1681000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1766000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
10691000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
12290000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
860000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11138000
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-35000
CY2014 us-gaap Revenues
Revenues
63548000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1597000
CY2014 us-gaap Investment Income Net
InvestmentIncomeNet
309000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
60431000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
727000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1152000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
820000
CY2014 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2014 us-gaap Net Income Loss
NetIncomeLoss
8170000
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4000000
CY2014 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
9493000000
CY2014 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
0
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27508000
CY2014 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
21236000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1084000
CY2014 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
67330000000
CY2014 us-gaap Interest Expense
InterestExpense
50000
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-4756000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2735000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4020000
CY2014 us-gaap Depreciation
Depreciation
2594000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1680000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1425000
CY2014 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-67000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3787000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2968000
CY2014 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
34804000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2072000
CY2015 dei Document Type
DocumentType
10-K
CY2014 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
214000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
122000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2480000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10475000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
52857000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
295000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4467000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
727000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1471000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2288000
CY2014 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
2821000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1766000
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17154000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2489000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-25000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19792000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28022000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1680000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5609000
CY2014 rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.015 pure
CY2014 rgen Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
-1036000
CY2014 rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-172000
CY2014 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
488000
CY2015 dei Trading Symbol
TradingSymbol
RGEN
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
310857 shares
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0000730272
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
695151 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5009 pure
CY2015 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042 pure
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
196209 shares
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.81
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5189 pure
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y29D
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentrations of Credit Risk and Significant Customers</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company&#x2019;s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December&#xA0;31, 2015 and 2014, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers&#x2019; financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Revenue from significant customers as a percentage of the Company&#x2019;s total revenue is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2015</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">GE Healthcare</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em; MARGIN-TOP: 0px; TEXT-INDENT: -1em"> <font style="FONT-FAMILY: Times New Roman" size="2">MilliporeSigma</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant accounts receivable balances as a percentage of the Company&#x2019;s total trade accounts receivable and royalties and other receivable balances are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2015</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,&#xA0;2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">GE Healthcare</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em; MARGIN-TOP: 0px; TEXT-INDENT: -1em"> <font style="FONT-FAMILY: Times New Roman" size="2">MilliporeSigma</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer C</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.091 pure
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.23
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32881940 shares
CY2015 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.304 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.009 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.142 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
15053000
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0167 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
117346 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.22
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
177693 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.45
CY2015 dei Entity Registrant Name
EntityRegistrantName
REPLIGEN CORP
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant estimates and assumptions by management affect the Company&#x2019;s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost method investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, fair value estimates of contingent consideration, contingent liabilities, tax reserves and recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</font></p> </div>
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M1D
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Organization and Nature of Business</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Repligen Corporation (&#x201C;Repligen&#x201D; or the &#x201C;Company&#x201D;) is a bioprocessing company that develops, manufactures and markets innovative products and solutions used to manufacture biologic drugs. The Company is a world-leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. Repligen also supplies several growth factor products, ATF System products and cell filtration products used to increase cell culture productivity during the bioproduction process. In the expanding area of flexible biomanufacturing technologies, the Company has developed and markets a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company generally manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, and ATF products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors. The Company manufactures its products in production facilities in the United States and Sweden.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"> <font style="font-family:Times New Roman" size="2">In addition, the Company has out-licensed certain intellectual property to Bristol-Myers Squibb Company, from which Repligen received royalties on Bristol&#x2019;s net sales in the United States of their product Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font>. On April&#xA0;7, 2008, the Company entered into a settlement agreement with Bristol in connection with a patent infringement lawsuit that Repligen filed against Bristol. Under the terms of the settlement agreement, Bristol was obligated to pay us royalties on its U.S. net sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font> for any clinical indication at a rate of 1.8% for the first $500,000,000 of annual sales, 2.0% for the next $500,000,000 of annual sales and 4% of annual sales in excess of $1 billion. Under the terms of the agreement, royalty payments on Bristol&#x2019;s sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">&#xAE;</sup></font> ceased as of December&#xA0;31, 2013.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company&#x2019;s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business and obtain adequate funding to finance this growth.</font></p> </div>
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0203 pure
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33577091 shares
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.027 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M10D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M21D
CY2015 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-158000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6552000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2628000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
866000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3598000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-445000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
13764000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
15913000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6149000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13423000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2015 us-gaap Revenues
Revenues
83537000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3729000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
136000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
83537000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1216000
CY2015 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
99000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4083000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2490000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
324000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
277000
CY2015 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2015 us-gaap Net Income Loss
NetIncomeLoss
9345000
CY2015 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
115000
CY2015 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
0
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20168000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2317000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2793000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2815000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
4948000
CY2015 us-gaap Interest Expense
InterestExpense
32000
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1882000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2619000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4594000
CY2015 us-gaap Depreciation
Depreciation
2996000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
767000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
276000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
4564000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4078000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
27587000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4083000
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
272000
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
295000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
563000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3745000
CY2015 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
161000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4942000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1139000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
69773000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-118000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18729000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1216000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-1910000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3024000
CY2015 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
3507000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3598000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24699000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1592000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-358000
CY2015 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
2115000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1153000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4791000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35251000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
866000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5740000
CY2015 rgen Lease Agreement Termination Description
LeaseAgreementTerminationDescription
The Company terminated the lease on the 7,350 square feet of space in the first quarter of 2015.
CY2015 rgen Lease Agreement Area
LeaseAgreementArea
45000 sqft
CY2015 rgen Nonrefundable Upfront Cash Payment Under Collaborations Agreement
NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
2000000
CY2015 rgen Marketable Debt Securities Weighted Average Remaining Maturity Period
MarketableDebtSecuritiesWeightedAverageRemainingMaturityPeriod
P5M24D
CY2015 rgen Long Term Marketable Securities Maturities Term Minimum
LongTermMarketableSecuritiesMaturitiesTermMinimum
P1Y
CY2015 rgen Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.009 pure
CY2015 rgen Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
2115000
CY2015 rgen Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
118000
CY2015 rgen Number Of Buildings Leased
NumberOfBuildingsLeased
4 Building
CY2015 rgen Provision For Deferred Income Tax Expense Benefit
ProvisionForDeferredIncomeTaxExpenseBenefit
333000
CY2015 rgen Amount To Be Received Upon Completion Of Transfer
AmountToBeReceivedUponCompletionOfTransfer
125675
CY2008 rgen Lease Agreement Area
LeaseAgreementArea
7350 sqft
CY2008 rgen Lease Agreement Term
LeaseAgreementTerm
P2Y
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31963000 shares
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31855000 shares
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
5308000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5398000
CY2014Q1 us-gaap Revenues
Revenues
16326000
CY2014Q1 us-gaap Investment Income Net
InvestmentIncomeNet
102000
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14335000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
4277000
CY2014Q1 us-gaap Royalty Revenue
RoyaltyRevenue
1991000
CY2014Q1 us-gaap Interest Expense
InterestExpense
14000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1121000
CY2014Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
98000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
11018000
CY2014Q1 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3384000
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6335000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1201000
CY2014Q1 rgen Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance
NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
2000000
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32755000 shares
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33451000 shares
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
132000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4039000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4198000
CY2015Q1 us-gaap Revenues
Revenues
20816000
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
36000
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
20816000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
2929000
CY2015Q1 us-gaap Interest Expense
InterestExpense
9000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1269000
CY2015Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1112000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
16777000
CY2015Q1 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6024000
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8073000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1568000
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32234000 shares
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33076000 shares
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
65000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3106000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3243000
CY2014Q2 us-gaap Revenues
Revenues
15551000
CY2014Q2 us-gaap Investment Income Net
InvestmentIncomeNet
85000
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
15551000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
2825000
CY2014Q2 us-gaap Interest Expense
InterestExpense
13000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
418000
CY2014Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
18000
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
12445000
CY2014Q2 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4326000
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6671000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1430000
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32870000 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33671000 shares
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-269000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
4609000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4351000
CY2015Q2 us-gaap Revenues
Revenues
21457000
CY2015Q2 us-gaap Investment Income Net
InvestmentIncomeNet
19000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21457000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
3613000
CY2015Q2 us-gaap Interest Expense
InterestExpense
8000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
738000
CY2015Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
768000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
16848000
CY2015Q2 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6242000
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8586000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1252000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32677000 shares
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33327000 shares
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2216000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2255000
CY2014Q3 us-gaap Revenues
Revenues
15278000
CY2014Q3 us-gaap Investment Income Net
InvestmentIncomeNet
64000
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
15153000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
1466000
CY2014Q3 us-gaap Royalty Revenue
RoyaltyRevenue
125000
CY2014Q3 us-gaap Interest Expense
InterestExpense
11000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
789000
CY2014Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
10000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
13062000
CY2014Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4471000
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6931000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1650000
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32925000 shares
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33690000 shares
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3688000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3679000
CY2015Q3 us-gaap Revenues
Revenues
19814000
CY2015Q3 us-gaap Investment Income Net
InvestmentIncomeNet
37000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
19814000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
2538000
CY2015Q3 us-gaap Interest Expense
InterestExpense
8000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1141000
CY2015Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
233000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
16126000
CY2015Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5959000
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8444000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1490000
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32747000 shares
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32747000 shares
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2014Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
134000
CY2015Q4 us-gaap Interest Expense
InterestExpense
8000
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
929000
CY2015Q4 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1969000
CY2015Q4 us-gaap Costs And Expenses
CostsAndExpenses
20021000
CY2015Q4 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2015Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6473000
CY2015Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10148000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1431000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
61000
CY2014Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
242000
CY2014Q4 us-gaap Revenues
Revenues
16393000
CY2014Q4 us-gaap Investment Income Net
InvestmentIncomeNet
59000
CY2014Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
15393000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-398000
CY2014Q4 us-gaap Royalty Revenue
RoyaltyRevenue
1000000
CY2014Q4 us-gaap Interest Expense
InterestExpense
12000
CY2014Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
640000
CY2014Q4 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1945000
CY2014Q4 us-gaap Costs And Expenses
CostsAndExpenses
16332000
CY2014Q4 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
0
CY2014Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4975000
CY2014Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8084000
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1328000
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32946000 shares
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33577000 shares
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-270000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
1428000
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1194000
CY2015Q4 us-gaap Revenues
Revenues
21449000
CY2015Q4 us-gaap Investment Income Net
InvestmentIncomeNet
44000
CY2015Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21449000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
265000

Files In Submission

Name View Source Status
0001193125-16-478518-index-headers.html Edgar Link pending
0001193125-16-478518-index.html Edgar Link pending
0001193125-16-478518.txt Edgar Link pending
0001193125-16-478518-xbrl.zip Edgar Link pending
d115476d10k.htm Edgar Link pending
d115476dex211.htm Edgar Link pending
d115476dex231.htm Edgar Link pending
d115476dex311.htm Edgar Link pending
d115476dex312.htm Edgar Link pending
d115476dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g115476g31f76.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgen-20151231.xml Edgar Link completed
rgen-20151231.xsd Edgar Link pending
rgen-20151231_cal.xml Edgar Link unprocessable
rgen-20151231_def.xml Edgar Link unprocessable
rgen-20151231_lab.xml Edgar Link unprocessable
rgen-20151231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending